{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-136025","form_type":"8-K","ticker":"DBVT","cik":"0001613780","company_name":"DBV Technologies S.A.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.668920+00:00","generated_at":"2026-06-15T22:06:36.728604+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"DBV Technologies Q1 net loss widens to $20.5M; cash drops to $192.3M","bullets":["Cash and equivalents $192.3M as of March 31, 2023, down from $209.2M at Dec 31, 2022.","Net loss of $20.5M for Q1 2023 vs $16.7M loss in Q1 2022; loss per share $0.22.","R&D expenses rose 31% to $16.0M, driven by initiation of VITESSE trial in March 2023.","Cash used in operations $20.8M vs $1.5M in Q1 2022; prior year included $20.9M French R&D tax credit receipt.","Total operating expenses $23.3M, up 21% from $19.3M in Q1 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-136025","json":"https://secwatch.observer/filing/0001193125-23-136025.json","markdown":"https://secwatch.observer/filing/0001193125-23-136025.md","text":"https://secwatch.observer/filing/0001193125-23-136025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613780/000119312523136025/0001193125-23-136025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613780/000119312523136025/d298404d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:06:36.728604+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cef8337834b6b4424ccea22c6014c0339d184cc5","claim":"DBV Technologies S.A. reported the fiscal quarter ended March 31, 2023 results: revenue 2.2, net income Net result for the three months ended March 31, 2023 is a loss amounting to $20.5 million, EPS $0.22 for the three months ended March 31, 2023.","evidence_excerpt":"Income In millions of USD Three months ended March 31, 2023 2022 Variation Research tax credits 1.8 1.5 +0.3 +20% Other operating income 0.4 1.0 -0.6 -60% Operating income 2.2 2.5 -0.3 -12% Operating income amounts to $2.2 million as of March 31, 2023, compared to $2.5 million as of March 31, 2022, which is a decrease of $0.3 million due to: (1) $0.3","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1613780/000119312523136025/0001193125-23-136025-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended March 31, 2023"},{"label":"Revenue","value":"2.2"},{"label":"Net income","value":"Net result for the three months ended March 31, 2023 is a loss amounting to $20.5 million"},{"label":"EPS","value":"$0.22 for the three months ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}